Document is current
Any future updates will be listed below
-
Authors
Johnson, Gretchen A.
Kodati, Bindu
Nahomi, Rooban B.
Pham, Jennifer H.
Krishnamoorthy, Vignesh R.
Phillips, Nicole R.
Krishnamoorthy, Raghu R.
Nagaraj, Ram H.
Stankowska, Dorota L. https://orcid.org/0000-0002-2541-6649
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Eye Institute (R01EY028179)
Research to Prevent Blindness (Gates Grubstake Award)
- License Information
-
More Information
Article History
Received: 22 February 2024
Revised: 3 June 2024
Accepted: 13 June 2024
First Online: 28 June 2024
Competing interests
: CPP-P1 technology to treat eye diseases has been licensed to Eyegenex, Inc. from the University of Colorado, Aurora, CO 80045. RHN is the Chief Scientific Advisor to Eyegenex, Inc. The authors declare no other possible conflicts of interest.
: This study was performed in accordance with the Declaration of Helsinki. Ethics approval from a committee is not required for the use of human tissue donated to the UNTHSC Willed Body Program because donor information is anonymous.
